Bayer's Skyla

Company: Bayer
Device: Skyla IUD
Drug delivered: levonorgestrel

Why it's important: For more than a decade, innovation in the field of intra-uterine devices for birth control has been stagnant, with no new hormone-releasing IUDs hitting the U.S. market during that time. But Bayer bucked the trend this year as it gained the FDA's approval for its long-lasting IUD, Skyla, which can stay implanted in the uterus and release the hormone levonorgestrel for up to three years.

IUDs in general are a hot topic as more and more experts tout their effectiveness over methods such as pills, patches and vaginal rings. And a hormone-releasing IUD can also be a cost-effective way to treat cancer of the lining of the uterus by reversing abnormal cell growth, studies have found.

By making headway in the growing IUD market, Bayer's Skyla is a delivery device to watch due to its potential to change the way both doctors and patients think about IUDs as a form of birth control.

For more:
Bayer's extended use IUD nets FDA go-ahead
EU green-lights Bayer's Jaydess hormone IUS
Dissolving fabric could stop pregnancy, HIV
Patch improves birth control compliance

Bayer's Skyla
Read more on

Suggested Articles

The new digital Abilify is a breakthrough for Proteus Digital Health and its patient-tracking products, but not so much for Abilify's maker, Otsuka.

Adamis Pharmaceuticals' EpiPen contender Symjepi, which was rejected last year before the EpiPen havoc, won approval from the FDA.

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.